Evidence map›Paper›PMID 33754696›Full record

ArticleBiochemistry2021

An Engineered Arginine Residue of Unusual pH-Sensitive Reactivity Facilitates Site-Selective Antibody Conjugation.

Napon Nilchan, James M Alburger, William R Roush, Christoph Rader

Abstract read
In one paragraph

Article in Biochemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Napon Nilchan
James M Alburger

Funding

Novel Enediyne-Based Antibody-Drug Conjugates for CancersR01CA204484 · NCI · UNIVERSITY OF FLORIDA · PI Natarajan Muthusamy, Ben Shen · 2017 to 2026
$4.6M
A Drug Delivery Strategy for Targeted Therapy of Chronic Lymphocytic LeukemiaR01CA174844 · NCI · UNIVERSITY OF FLORIDA · PI SHEN, BEN · 2018 to 2022
$3.0M
NCI NIH HHS R01 CA174844NCI NIH HHS R01 CA204484
6 · The paper itself

Abstract

Monoclonal antibody h38C2 is a humanized catalytic antibody that has been used to generate various immunoconjugate species such as chemically programmed antibodies, antibody-drug conjugates, and antibody-siRNA conjugates. Highly efficient and specific conjugation of h38C2 occurs at its uniquely reactive lysine (Lys) residue buried inside the antibody's catalytic pocket. We recently reported the rational mutation of this Lys residue at position 99 in the heavy chain variable domain to an arginine (Arg) residue. The Lys99Arg mutation can be site-selectively conjugated with molecules containing a hapten-like triazolyl-phenylglyoxal (TPG) unit. Here we show that this conjugation is facilitated by the unusual pH-sensitive reactivity of the Arg99 residue, consistent with an indirectly measured p

Indexed as

ArginineImmunoconjugatesAntibodies, CatalyticAntibodies, MonoclonalHumansHydrogen-Ion ConcentrationLysineProtein EngineeringAntibodies, CatalyticAntibodies, MonoclonalArginineImmunoconjugatesLysine

Identifiers

PMID33754696
PMCPMC8852817

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.